Trial Profile

Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Filgrastim (Primary) ; Loperamide (Primary) ; Sacituzumab govitecan (Primary) ; Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms PRIMED

05 Dec 2024 According to MEDSIR media release, the company will present the data from this study at San Antonio Breast Cancer Symposium 2024.
04 Jun 2024 Results assessing Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 Jun 2024 Results published in a MEDSIR media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com